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Abstract
Background: Stimulants are highly effective in controlling symptoms of Attention-deficit/hyperactivity disorder (ADHD), but 30%
of individuals with ADHD do not respond to them or cannot tolerate their side effects; thus, alternative treatment approaches need
to be considered.
Objectives: To evaluate the effect and safety of piracetam as an adjuvant therapy plus methylphenidate (MPH) in children with
ADHD.
Methods: Thirty-six children with ADHD (6-16 years old), admitted to three academic outpatient child psychiatric clinics in the sec-
ond half of 2015, were randomly assigned to the “methylphenidate plus piracetam group” and the “methylphenidate plus placebo”
group, in a double-blind, placebo-controlled study, for 6 weeks. The “Conner’s Parents’ Rating Scale-Revised (CPRS-R), Children Symp-
tom Inventory-4 (CSI-4), Clinical Global Impression-Improvement scale (CGI-I), and Children’ Global Assessment Scale (CGAS) were
completed at baseline and at the ends of the third and the sixth week, and the New York State Psychiatric Institute side effect forms
were completed weekly, as outcome measures.
Results: The level of improvement in CPRS-R, CSI-4, and CGI-I scales were significantly higher in the “methylphenidate plus pirac-
etam” group compared with the “methylphenidate plus placebo” group. Side effects were not remarkable in any group.
Conclusions: Piracetam as a short-term adjuvant treatment to methylphenidate can have considerable therapeutic effect and safety
profile in children with ADHD and deserves further exploration to assess its potentialities in ADHD treatment.
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1. Background
Attention-deficit/hyperactivity disorder (ADHD) is a
neurodevelopmental psychiatric condition, with a preva-
lence of 5 - 10% (1). It results from developmental dysfunc-
tions of various brain areas, mainly the prefrontal cortex
(2, 3). Stimulants are highly effective in controlling symp-
toms of ADHD in 75% of patients (4, 5), but 30% of individu-
als with ADHD do not respond to these medications or can-
not tolerate their side effects (4). Thus, alternative treat-
ment approaches need serious consideration.
Nootropics are psychoactive medications with
stimulant-like effects (6). Piracetam is one of the nootropic
medications (7) and can facilitate brain blood flow, cere-
bral oxygen bioavailability (8), and brain metabolism rate
(9). Studies have shown that piracetam acts on neuronal
membrane, increases synaptic neurotransmitter release,
enhances neuron excitability, and stimulates the cere-
bral cortex (10). Piracetam has been studied in several
cognitive and neurodevelopmental disabilities (11) and
in different age ranges, and results have shown that it is
well-tolerated, with almost no side effects or drug-drug
interaction (12). Piracetam seems to improve alertness
(11), attention span, and concentration (13), eye-hand co-
ordination (11), memory (13), learning (11), and language
function (13). Considering the mentioned documents, it
can be hypothesized that piracetam may be effective in
reducing symptoms of ADHD and could be an appropriate
candidate for therapeutic purposes in this disorder.
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There are only two published studies on the effect of
piracetam in children with ADHD. These controlled open
trials used piracetam as monotherapy at the doses of 40 -
70 mg/kg/day for 4 - 6 weeks in ADHD children aged 6 - 13
years. Both studies demonstrated the high effectiveness of
piracetam in reducing ADHD symptoms and its superiority
over placebo, with more response rate at higher doses (14,
15). Given the paucity of studies on the effect of piracetam
on ADHD and their open design, which demonstrated pos-
itive outcomes, performing more precisely designed trials
on greater sample sizes and wider age ranges seems neces-
sary.
2. Objectives
The present study was performed to evaluate the
short-term effects of piracetam as adjuvant therapy
in children with ADHD who were under treatment of




Our sample consisted of 36 children of both genders
who were admitted to outpatient child psychiatric clinics
of Iran University of Medical Sciences (IUMS) during the
second half of 2015.
Inclusion criteria were: (1) being 6 - 16 years old;(2) diag-
nosed as having ADHD by DSM-IV-TR criteria (16), the ADHD
section of Child Symptom Inventory-DSM-IV-Version (CSI-
4), Kiddie Schedule for Affective Disorders and Schizophre-
nia, Present and Lifetime Version (KSADS-PL), and the clin-
ical judgment of child psychiatrist; (3) being drug-naïve;
(4) good health on medical review of systems and com-
plete routine physical and neurological examinations, and
(5) having written informed consent from parents and as-
sents from patients. The exclusion criteria were: (1) having
any comorbid major mood, psychotic, neurologic, devel-
opmental, or medical disorders, or substance use (2) hav-
ing an intellectual disability; and (3) being under any ther-
apy during the study.
To include an ordinary group of patients with ADHD,
children with common comorbidities of ADHD (18) were
not excluded from the study. The study’s protocol was
registered at the Iranian Registry of Clinical Trials (regis-
tration number: IRCT201303036923N2), approved by the
Committee of Medical Ethics of IUMS (number: 19912), and
granted by the Mental Health Research Center of IUMS
(grant number: 19912-121-04-91).
3.2. Measurements
Subjects were evaluated by the following tests: (1)
Kiddie Schedule for Affective Disorder and Schizophrenia,
Present and Lifetime Version (KSADS-PL) (17) at baseline for
diagnosing ADHD and other co-morbidities; (2) ADHD sec-
tion of the Child Symptom Inventory-DSM-IV-Version (CSI-
4) (18, 19) as diagnostic and severity assessment tool; 3) Con-
ner’s Parents Rating Scale (CPRS-R) (20) to assess the sever-
ity of ADHD; (4) Clinical Global Impression-Improvement
(CGI-I) scale (21) to assess the degree of improvement;
(5) Children’s Global Assessment Scale (CGAS) (22) to esti-
mate functional status; (6) complete medical review of sys-
tems, and complete physical and neurological examina-
tion (height, weight, pulse rate, and blood pressure); and
(7) New York State Psychiatric Institute side effect form for
the clinical trial in children and adolescents (23) for weekly
assessment of medication adverse effects. KSADS-PL was
completed at baseline. Other tools were used at baseline
and after the third and sixth weeks of the study. All tests
are validated, and their reliabilities are approved in Persian
(24, 25).
3.3. Procedure
This study was a short-term, randomized, double-
blind, placebo-controlled, clinical trial. Participants were
randomly assigned to either the “MPH plus piracetam”
group or the “MPH plus placebo” group, for six weeks in
a 1:1 ratio using a computer-generated code. Parents, pa-
tients, and rater were blind to group assignments. The
treatment protocol for titrating up of MPH during the
study was as follows: starting at 5 mg in morning and
mid-day, and weekly increase of 5 mg in each dose until
the maximum dose of 40 mg per day during the fourth
week. The MPH dose was adjusted for the fifth and the
sixth week considering the best dose-treatment response
during the first to the fourth week. Methylphenidate
was 10 mg round tablets in 20’s blisters, and piracetam
was 33.3% in 120 mL liquid preparation. The liquid forms
of piracetam and placebo (DarouPakhsh Pharmaceutical
Company, Tehran, Iran) were similar in color, smell, taste,
and viscosity, and their containing bottles were identical
in size, shape, weight, and general appearance. The com-
pany did not interfere in other parts of the study. The se-
quentially numbered containers (SNCR) method was used
for randomization. One of the researchers allocated the
bottles with the code of A or B to the subjects, and an-
other researcher (a senior resident of psychiatry) who was
blind to the groups, performed the assessments. As 50 - 70
mg/kg/day is the recommended and well-tolerated dose of
piracetam in children (12, 14), a fixed-dose of 60 mg/kg/day
in three divided doses was chosen to be administered from
the beginning of the first week until the end of the sixth
week of the trial for the subjects in the MPH plus piracetam
group. Weekly contacts were maintained with subjects and
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their parents to fill the side effects form and CGI-I at the end
of each week; and CPRS-R, CSI-4, and CGAS at the ends of
the third and the sixth week. Detailed progress notes were
recorded after each contact, as well. Compliance was eval-
uated by collecting the remaining medication (at the end
of the third and the sixth week) and calculating the differ-
ence.
3.4. Ethical Considerations
Participation in the research was voluntary, and in-
formed consent and assent were obtained from parents
and patients. Both groups received standard medication
for ADHD and also piracetam, which was used as add-on
treatment and as a well-tolerated medication without se-
rious side effects or drug-drug interaction (12). Subjects’
information was protected confidentially, and they could
withdraw at any time without reprisal.
3.5. Statistical Analysis
Statistical analysis was done using IBM SPSS Statistics
22. Variables were reported descriptively by mean, stan-
dard deviation (SD), and frequency. Comparison of the fre-
quencies of nominal variables was carried out using the
chi-square test or Fisher’s exact test. The effectiveness of
the treatment was first reported based on paired t-test for
outcome measures in each time set. Also, all outcome mea-
sures were compared according to the results of repeated
measures analysis of variance (ANOVA), considering time
as a fixed factor (within-subject variable) and treatment
group as between-subject variable. A P-value of less than
0.05 was considered statistically significant.
4. Results
Thirty-six out of the initial 40 subjects who were en-
rolled in the study completed the whole six-week trial (Fig-
ure 1). Four cases left the study before starting the trial: Two
cases due to starting interventions for a learning disorder,
one case due to immigration, and one case without clear
explanation.
The baseline characteristics and comorbidities of sub-
jects are described in Tables 1 and 2. Accordingly, the two
groups did not differ significantly in distribution of either
baseline demographic or clinical characteristics. Review of
systems and physical and neurological examinations in all
subjects were within the normal range at baseline and at
the ends of the third and the sixth week, and the patients
were in the good clinical condition in all visits.
4.1. Therapeutic Effect
Tables 3 and 4 show the therapeutic effect of medica-
tion packages. According to Tables 3 and 4, the two groups
were similar and not statistically different in any of the
tests’ scores at baseline. The CPRS and CSI-4 scores showed
a significant decrease from baseline to the end of the third
and the sixth week in both groups. The CGAS scores in-
creased significantly in both groups during the same time
(Tables 3 and 4). Tables 3 and 4 indicate that subjects in the
“MPH plus piracetam” group had lower scores in CPRS and
CSI-4 at the ends of the third and the sixth week in compari-
son with the subjects in the “MPH plus placebo” group and
the differences between groups were statistically signifi-
cant. Although CGAS scores changed significantly within
each group during the follow-up period, with subjects of
the “MPH plus piracetam” group had higher scores; the
changes were not significantly different between groups
(Tables 3 and 4). Based on the CGI-I scale, 83.3% of subjects
in the “MPH plus piracetam” group and 38.8% of subjects
in the” MPH plus placebo” group experienced much to very
much improvement at the end of the third week, and a sig-
nificant difference was found between two groups in this
regard (P = 0.01, χ = 5.6). At the end of the sixth week,
the number of subjects with this level of improvement in-
creased to 88.8% in the “MPH plus piracetam” group and
to 66.6% in the “MPH plus placebo” group which was not
significantly different (χ2 = 2.57, P = 0.1). This indicates that
the therapeutic effect had an earlier onset in the “MPH plus
placebo” group.
4.2. Adverse Effects
Table 5 shows the side effects profile. There was no
significant difference in side effects between treatment
groups. All the mentioned adverse effects were mild, self-
limited, not experienced longer than 4 days, and did not
interfere with functioning. No subject left the trial because
of the adverse effects.
5. Discussion
The pharmaceutical approach is the main treatment
modality in ADHD (1), with stimulants known as the first-
line treatment (4). However, they cannot be of benefit in a
minority of patients (4). Thus, alternative pharmacologic
approaches need to be considered seriously. The present
study was the first randomized, double-blind, placebo-
controlled study, which was performed on children with
ADHD, in order to evaluate the effectiveness and safety of
piracetam in them. Subjects in both groups demonstrated
a significant reduction in ADHD severity and significant
improvement in their functioning status during the study.
Based on CPRS-R and CSI-4, the decrease in disorder severity
had an earlier onset and was more prominent in the pirac-
etam adjunction group. The weight-based dose of pirac-
etam (60 mg/kg/day) used in this trial was within the rec-
ommended dose range of piracetam (9-12, 14, 15), and the
outcome measures were known as appropriate measures,
which are commonly used in treatment studies of ADHD (5,
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458 individuals referred to the child and adolescent outpatient
psychiatric clinics of the Iran University of Medical Sciences (IUMS)
in the second half of 2015
284 had ADHD
72 were eligibible for the study
32 did not give consent or








one case: starting therapeutic
interventions for comorbid
learning disorder
one case: migration to another
city
2 withdrawn:
one case: starting therapeutic
interventions for comorbid
learning disorder
one case: unknown reason
18 completed the study18 completed the study
Figure 1. Enrollment profile
18-22). In some cases, optimal doses of MPH may be accom-
panied by problematic side effects, which result in dose
reduction. However, reduced doses are sometimes associ-
ated with symptoms rebound (4). In such cases, adjuvant
therapy may compensate for this problem without exert-
ing additional side effects. Functioning scores based on
the CGAS were not affected by the combination of MPH and
piracetam in comparison with the control group. Thera-
peutic effects of the adjuvant experimental medication on
the functioning status might be obscured by the promi-
nent effect of MPH in improving the functional domain of
the subjects. Also, it is probable that the small sample size
and a short period of the present study might not be suf-
ficient to discover the role of piracetam in the improve-
ment of functional status. Subjects in both groups were in
good health in all visits. Side effects experienced in both
groups were generally mild and did not lead to functional
impairment or nonadherence. Similar to our findings, sev-
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Table 1. Baseline Characteristics of the Studied Children








Male 14 15 χ2 = 0.125 0.723
Female 6 5
Educational level (Fr)
Preliminary 16 16 - -
Higher levels 2 2
Age, y (mean ± SD) 9.4 ± 2.0 9.6 ± 2.4 t = 0.227 0.822
Height, cm (mean ± SD) 135.9 ± 11.4 137.7 ± 15.6 t = 0.391 0.698
Weight, Kg (mean ± SD)
Baseline 31.3 ± 8.2 33.1 ± 12.3 t = 0.512 0.612
After 6 weeks 31.3 ± 8.1 32.8 ± 12.3 t = 0.450 0.656
Type of ADHD
Combined 11 12 χ2 = 0.110 0.996
Inattentive 8 7
Hyperactive/impulsive 1 1
Abbreviations: MPH: methylphenidate; ADHD: attention-deficit/hyperactivity disorder; Fr: frequency; SD: standard deviation.
aFisher’s exact test.
Table 2. Frequency of Comorbid Psychiatric Disorders among Participants
Disorder MPH Plus Piracetam (N = 20) MPH Plus Placebo (N = 20)
Statistical Comparison
χ2 P-Value
Oppositional defiant disorder 10 8 0.404 0.525
Obsessive-compulsive disorder 4 6 0.533 0.465
Learning disorders 10 11 0.100 0.752
Tic disorders 2 0 2.105 0.487a
Phobia 1 2 0.360 1.000a
Enuresis 0 1 1.026 1.000a
Abbreviation: MPH: methylphenidate.
aFisher’s exact test.
eral studies have shown few side effects with piracetam use
(8, 10-12).
ADHD results from a developmental lag in CNS func-
tioning and cortical hypo arousal, and some brain areas,
which are involved in cognition processing show abnor-
mally low activation rates in ADHD during neurocognitive
tasks (1-3). Piracetam is a cerebroactive medication that can
improve brain metabolism, information processing, inte-
gration and transfer, and global mental and cognitive func-
tions (9-13, 16). Its mechanism of action is based on enhanc-
ing mental acts through facilitating the activity of cholin-
ergic, dopaminergic, and noradrenergic systems, main-
taining and protecting neuron receptors, and reestablish-
ing impaired neurotransmission (16). These properties of
piracetam can be considered as the probable factor for the
positive effect of this drug on ADHD.
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Table 3. Subjects’ Score (Mean± SD) On Conners’ Parents Rating Scale, Children’s Global Assessment Scale, and Child Symptom Inventory-DSM-IV-Version at Baseline and After
Three and Six Weeks of Treatments




Baseline 50.9 ± 9.5 51.7 ± 7.6 0.194 0.848
Third week 21.2 ± 9.9 29.6 ± 7.3 2.911 0.006
Sixth week 26.8 ± 7.9 13.5 ± 10.9 4.203 <0.001
CGAS
Baseline 53.8 ± 8.3 52.0 ± 8.0 0.658 0.515
Third week 71.2 ± 6.4 69.9 ± 6.2 0.610 0.546
Sixth week 73.7 ± 6.3 70.7 ± 17.5 0.673 0.506
CSI-4
Baseline 35.1 ± 7.9 37.2 ± 7.0 0.856 0.398
Third week 14.8 ± 8.2 21.7 ± 5.8 2.933 0.006
Sixth week 9.2 ± 7.7 18.0 ± 4.9 4.096 <0.001
Abbreviations: CGAS, Children’s Global Assessment Scale; CPRS-R, Conners’ Parents Rating Scale; CSI-4, Child Symptom Inventory-DSM-IV-Version; MPH, methylphenidate;
SD, standard deviation.
Table 4. Summary of Statistical Comparisons of the Two Groups of Treatment According to Repeated Measurement Analysis of Variance
Rating Score & Source F df P-Value ES (Partial η2) Power
CPRS-R
Time 232.9 1.206 < 0.001 0.873 1.000
Time * group 8.752 1.206 0.003 0.205 0.869
CGAS
Time 76.9 1.365 < 0.001 0.693 1.000
Time * group 0.123 1.365 0.805 0.004 0.065
CSI-4
Time 188.9 1.287 < 0.001 0.847 1.000
Time * group 3.944 1.287 0.044 0.104 0.555
Abbreviations: CPRS-R: Conner’s parents’ rating scale; CGAS: Children’s Global Assessment Scale; CSI-4: child symptom inventory-DSM-IV-version; ES: effect size.
There are very few researches available in the litera-
ture evaluating the possible therapeutic effect of pirac-
etam on ADHD. Zavadenke and Suvorinova (2004) evalu-
ated the therapeutic efficacy of two different doses of pirac-
etam (40 mg/kg/day vs. 70 mg/kg/day) in an open con-
trolled study on children with ADHD. Attention, behavioral
characteristics, and motor coordination were improved in
both groups, but the response rate was higher in those re-
ceiving higher doses of piracetam (14). In another open
controlled study on children with ADHD, it was found that
monotherapy of piracetam was highly effective in compar-
ison with no pharmacological treatment (15). Our study,
which was a double-blind, placebo-controlled randomized
trial, consisting larger sample size, revealed almost simi-
lar positive therapeutic effects of piracetam as an adjuvant
treatment in ADHD. Based on the results of this study, it
seems that adjuvant piracetam was effective in decreasing
the severity of ADHD symptoms and could reinforce earlier
onset and higher therapeutic effects of MPH.
5.1. Limitations
Limitations of the present study, which hinder the ex-
pansion of findings were: (1) small sample size; (2) re-
stricted age range; (3) using only referral outpatient cases;
(4) short duration (6 weeks) of the follow-up period; and (5)
not being able to use Conner’s Teachers Rating Scale (CTRS),
because parent’s concern about their child being stigma-
tized at school.
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Table 5. Frequency of Adverse Effects Related to the Medications in Participants
Disorder MPH Plus Piracetam MPH Plus Placebo Test
Statistical Comparison
χ2 P-Value
Abdominal pain 5 6 Chi-square test 0.131 0.717
Anxiety 5 3 Chi-square test 0.643 0.423
Decreased appetite 9 11 Chi-square test 0.450 0.502
Sleep disturbance 10 7 Chi-square test 1.003 0.317
Drowsiness 1 2 Fisher’s exact test 0.364 1.000
Dry mouth 3 2 Fisher’s exact test 0.232 1.000
Headache 4 3 Chi-square test 0.177 0.674
Irritability 5 6 Chi-square test 0.131 0.717
Nausea 3 2 Fisher’s exact test 0.232 1.000
Palpitation 1 2 Fisher’s exact test 0.364 1.000
Restlessness 4 2 Fisher’s exact test 0.800 1.000
5.2. Conclusion
The findings of this study provide evidence of posi-
tive therapeutic effects and negligible side effect profile of
piracetam (60 mg/kg/day) as an adjuvant medication, in
the short-term treatment of children with ADHD who are
receiving MPH. This medication seems to deserve further
comprehensive studies, to explore its efficacy and safety in
the treatment of children with ADHD.
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